Rehabilitacion · 2026
[Hyaluronic acid vaginal injections in moderate-to-severe vulvovaginal atrophy: a pre-post pilot study in a pelvic floor rehabilitation unit].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Romero-Cullerés G, Prados-Romero L, Jané-Feixas C, Arnau-Bartes A
Аннотация
OBJECTIVE: To evaluate the efficacy and safety of cross-linked hyaluronic acid vaginal injections in women with moderate-to-severe vulvovaginal atrophy (VVA) treated in a pelvic floor rehabilitation unit.
MATERIAL AND METHODS: Pilot, quasi-experimental, prospective pre-post study designed to assess safety and detect a preliminary signal of clinical benefit following a single vaginal hyaluronic acid injection, without confirmatory intent. The primary efficacy endpoint was the pre-post change in the Vulvar Health Index (VHI). Eleven women with moderate or severe VVA were included, most with a history of hormone-dependent breast cancer and contraindications to hormonal therapy. A single 1-mL injection of hyaluronic acid was administered, and clinical and functional parameters were assessed using the following tools: VHI, Female Sexual Function Index (FSFI), Visual Analog Scale (VAS) for pain, vulvovaginal symptom questionnaire, dyspareunia grade, Modified Oxford Scale, and the Patient and Clinician Global Impression of Improvement (PGI-I, CGI-I).
RESULTS: At 30 days, VHI improved significantly (11.4±2.9 to 7.8±3.2; p<0.001), FSFI increased (7.2 to 15.3; p=0.008), and pain decreased (VAS: 7.4±1.4 to 3.0±2.4; p<0.001). Overall, 72.7% of patients rated themselves as "very much improved" or "much improved," and no adverse events were reported.
CONCLUSIONS: Vaginal hyaluronic acid injections may represent a safe and effective therapeutic option for women with severe VVA, particularly those with oncological history. Larger controlled studies with extended follow-up are needed to confirm these preliminary findings.
MATERIAL AND METHODS: Pilot, quasi-experimental, prospective pre-post study designed to assess safety and detect a preliminary signal of clinical benefit following a single vaginal hyaluronic acid injection, without confirmatory intent. The primary efficacy endpoint was the pre-post change in the Vulvar Health Index (VHI). Eleven women with moderate or severe VVA were included, most with a history of hormone-dependent breast cancer and contraindications to hormonal therapy. A single 1-mL injection of hyaluronic acid was administered, and clinical and functional parameters were assessed using the following tools: VHI, Female Sexual Function Index (FSFI), Visual Analog Scale (VAS) for pain, vulvovaginal symptom questionnaire, dyspareunia grade, Modified Oxford Scale, and the Patient and Clinician Global Impression of Improvement (PGI-I, CGI-I).
RESULTS: At 30 days, VHI improved significantly (11.4±2.9 to 7.8±3.2; p<0.001), FSFI increased (7.2 to 15.3; p=0.008), and pain decreased (VAS: 7.4±1.4 to 3.0±2.4; p<0.001). Overall, 72.7% of patients rated themselves as "very much improved" or "much improved," and no adverse events were reported.
CONCLUSIONS: Vaginal hyaluronic acid injections may represent a safe and effective therapeutic option for women with severe VVA, particularly those with oncological history. Larger controlled studies with extended follow-up are needed to confirm these preliminary findings.